NYSE · CIK 0001099800 · ORTHOPEDIC, PROSTHETIC & SURGICAL APPLIANCES & SUPPLIES
Edwards Lifesciences Corporation
EW chart by TradingView
PRICE HISTORY
LIVE · NYSEEW chart by TradingView
- REVENUE FY2025 ENDED DEC 2025
- $6.1B
- EBITDA
- $1.4B
- FREE CASH FLOW
- $1.3B
- EPS
- $1.83
- GROSS MARGIN
- 78.01%
- ROIC
- 13.42%
Q2 FY26ENDED JUN 2026HOVERDRAG ACROSS ANY CHART TO SCRUB ALL 24 · 40 QUARTERS SHOWNVALUATIONGROWTHPROFITABILITY & RETURNSCASH & CAPITALBALANCE SHEET
VALUATION
what you pay for a unit of the business7 CHARTS⤢
P / E RATIO (TTM)
52.0x
+9%9.5x69.9x
⤢
P / SALES (TTM)
8.0x
-13%6.5x15.6x
⤢
P / BOOK
4.9x
-50%4.1x14.0x
⤢
EV / EBITDA (TTM)
30.9x
+47%21.0x56.7x
⤢
EV / REVENUE (TTM)
7.7x
-16%6.5x15.6x
⤢
FCF YIELD (TTM)
2.74%
+1.0pp0.47%3.42%
⤢
DIVIDEND YIELD (TTM)
—
GROWTH
is the business getting bigger5 CHARTS⤢
REVENUE
$1.7B
+135%⤢
EBITDA (DERIVED)
$0.6B
+74%⤢
NET INCOME
$0.2B
+71%⤢
EPS (DILUTED)
$0.42
+94%⤢
REVENUE GROWTH YOY
13.63%
-6.5pp-67.67%135.29%
PROFITABILITY & RETURNS
what survives to the bottom, and what it earns on capital4 CHARTS⤢
FCF MARGIN
33.60%
+12.3pp-12.79%49.76%
⤢
RETURN ON CAPITAL
12.09%
-8.7pp12.09%64.31%
⤢
RETURN ON EQUITY (TTM)
9.46%
-11.0pp9.46%43.57%
MARGIN FUNNEL
every line is a share of the same revenue, so they read on one scale — the gaps are what each layer takes out, and net rises above operating when income arrives from outside the businessGROSS MARGIN77.46%
OPERATING MARGIN29.48%
NET MARGIN13.89%
FCF MARGIN33.60%
CASH & CAPITAL
where the money actually goes5 CHARTS⤢
FREE CASH FLOW
$0.6B
+271%⤢
STOCK-BASED COMP
$0.0B
+193%⤢
CAPITAL EXPENDITURE
$0.1B
+39%⤢
SHARES OUTSTANDING
0.58B
-12%⤢
DIVIDEND / SHARE
—
BALANCE SHEET
how much cushion there is3 CHARTS⤢
CASH & EQUIVALENTS
$2.9B
+351%⤢
TOTAL DEBT
$0.6B
-0%⤢
DEBT / EBITDA (TTM)
0.4x
-58%0.3x1.1x
OWNERSHIP
10 LARGEST HOLDERS · WHO OWNS THE FLOATINSTITUTIONS 93.53%INSIDERS 0.18%OTHER / RETAIL 6.29%1,910 INSTITUTIONAL FILERS
| HOLDER | % HELD | SHARES | VALUE | CHANGE |
|---|---|---|---|---|
| Blackrock Inc. | 9.13% | 52.6M | $4.72B | +0.3% |
| Vanguard Capital Management LLC | 6.55% | 37.7M | $3.38B | NEW |
| Vanguard Portfolio Management LLC | 4.59% | 26.4M | $2.37B | NEW |
| State Street Corporation | 4.57% | 26.3M | $2.36B | +1.2% |
| Wellington Management Group, LLP | 3.82% | 22.0M | $1.97B | +1.0% |
| JPMORGAN CHASE & CO | 3.78% | 21.7M | $1.95B | -16.5% |
| FMR, LLC | 2.52% | 14.5M | $1.30B | -12.5% |
| Bank Of New York Mellon Corporation | 2.45% | 14.1M | $1.26B | -15.8% |
| Geode Capital Management, LLC | 2.28% | 13.1M | $1.18B | +2.7% |
| Dz Bank Ag Deutsche Zentral Genossenschafts Bank, Frankfurt Am Main | 2.23% | 12.8M | $1.15B | +65.7% |
AS OF 2026-03-31 · MOST RECENT 13F FILINGS
SOURCE → 10-K · 10-Q · 8-K / GUIDANCE · ALL FILINGS
FILING DATA AS OF 2026-08-10. Figures are derived from public SEC EDGAR filings (40most recent quarters shown, Q4 implied as full-year minus Q1-Q3). Valuation multiples use each period’s fiscal period-end close. Live price charts and quotes are provided by TradingView. This page is informational only — it is not investment advice, and figures are not warranted for accuracy. EBITDA is not a GAAP measure; it is derived as operating income + D&A. Verify against the linked source filing before relying on any number here.
FILING DATA AS OF 2026-08-10. Figures are derived from public SEC EDGAR filings (40most recent quarters shown, Q4 implied as full-year minus Q1-Q3). Valuation multiples use each period’s fiscal period-end close. Live price charts and quotes are provided by TradingView. This page is informational only — it is not investment advice, and figures are not warranted for accuracy. EBITDA is not a GAAP measure; it is derived as operating income + D&A. Verify against the linked source filing before relying on any number here.